摘要
目的探讨PTEN和Cyclin D1在口腔鳞癌(OSCC)组织中的表达及其与预后的相关性。方法回顾性分析接受手术±放疗的OSCC患者78例的临床资料;采用免疫组织化学法检测肿瘤原发灶中PTEN和Cyclin D1蛋白的表达,统计分析其表达水平与临床病理参数及生存状态的关系。结果PTEN和Cyclin D1高、中、低表达分别为22例(28.2%)、47例(60.3%)、9例(11.5%)和39例(50.0%)、29例(37.2%)、10例(12.8%)。PTEN表达和Cyclin D1表达无统计学相关(γ=0.114,P=0.320)。中位随访33.35(4.7~51.4)个月。全组3y-OS和3y-DFS分别为65.4%和53.8%。多因素分析结果显示:PTEN低表达(P=0.046)和Cyclin D1高表达(P=0.011)是影响患者无病生存的不良预后因素,PTEN低表达(P=0.049)也是影响患者总生存的不良预后因素。结论PTEN和Cyclin D1的表达水平与OSCC的患者的预后相关,对评估OSCC患者的预后有一定的价值。
Objective To investigate the expression of PTEN and Cyclin D1 in oral squamous cell carcinoma(OSCC),and to explore their prognostic significance.Methods Clinical data of 78 patients with OSCC who underwent surgery with or without postoperative radiotherapy were collected and analyzed.The expression of PTEN and Cyclin D1 were detected using the immunohistochemistry method.Statistic correlation between their expression level,correlation of their expression with clinicopathological parameters,and the impact of their expression on survival status of the patients were analyzed.Results 78 patients with OSCC were enrolled,including 48 males and 30 females.The median age was 60,ranging from 34 to 83.The median follow-up time was 33 months,ranging from 4 to 51 months.3y-OS and 3y-DFS were 65.4%and 53.8%respectively.The high,medium and low expression levels of PTEN and Cyclin D1 were 22(28.2%),47(60.3%),9(11.5%)and 39(50.0%),29(37.2%)and 10(12.8%)respectively.There was no statistical correlation between the expression of PTEN and Cyclin D1(γ=0.114,P=0.320).Multivariate analysis using Cox regression demonstrated that low expression of PTEN and over expression of Cyclin D1 were independent adverse factors of OSCC.Conclusion The expression of PTEN and Cyclin D1 were correlated with the prognostic of OSCC patients,which is of certain value in evaluating the prognostic of OSCC patients.
作者
冯钦
洪晨善
魏晓龙
曾芸珠
许少伟
彭汉伟
FENG Qin;HONG Chenshan;WEI Xiaolong(Cancer Hospital of Shantou University Medical College,Shantou,515031)
出处
《实用癌症杂志》
2020年第8期1235-1239,共5页
The Practical Journal of Cancer
基金
广东省高水平大学重点学科建设项目(编号:2015030)。